Novartis AG plans to pay Cytos Biotechnology AG up to $500 million for exclusive rights to develop, produce and market a drug designed to help individuals cure their smoking habit. The Swiss firm's NicQb, billed as an anti-smoking vaccine, is in clinical trials. It blocks the nicotine rush people experience when smoking a cigarette.

Full Story:

Related Summaries